SPHDF OTC
Santhera Pharmaceuticals Holding AG
1W: -7.5%
1M: -21.3%
3M: -21.3%
YTD: +37.1%
1Y: +37.4%
3Y: +2591.2%
5Y: +115722.8%
$18.30
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$271.4M
52W Range12.27-23.25
Volume100
Avg Volume259
Beta-0.28
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOOrlando Oliveira
Employees78
SectorHealthcare
IndustryBiotechnology
IPO Date2014-07-01
Websitesanthera.com
Hohenrainstrasse 24
Pratteln, BL 4133
CH
Pratteln, BL 4133
CH
41 61 906 89 50
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Latest News
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
Santhera Pharmaceuticals: Delivers life-changing treatment to little fanfare. Soon the numbers will support its progress
Santhera lands key approval for DMD treatment in Switzerland
Santhera lands key approval for DMD treatment in Switzerland
Aritzia shares rise as Q3 earnings top expectations
Recent Insider Trades
No insider trades found